Early Stage Breast Carcinoma
13
5
8
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
1 terminated out of 13 trials
75.0%
-11.5% vs benchmark
8%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer
Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer
Sentinel Node Vs Observation After Axillary Ultra-souND
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer
Observational Trial on the Impact of Hypnose Used as a Sedation in Oncology Surgery in Breast Cancer